Holen Sie sich die Stockscreener-App
16.99
0.06%
-0.0516
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences confirms UM test’s efficacy - Investing.com
Castle Biosciences (CSTL) Presents New Data on Uveal Melanoma Ri - GuruFocus
Castle Biosciences confirms UM test’s efficacy By Investing.com - Investing.com South Africa
Castle Biosciences to buy Previse - MSN
Castle Biosciences Reports Independent Validation of DecisionDx-UM Test with PRAME Gene Expression Data at ARVO 2025 - Nasdaq
Real-World Study Confirms Long-Term Performance of - GlobeNewswire
Texas public company to acquire Baltimore cancer diagnostic firm - The Business Journals
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences (CSTL) Champions Skin Cancer Awareness Initiatives | CSTL Stock News - GuruFocus
Castle Biosciences Partners with Melanoma Organizations to Promote Skin Cancer Awareness and Education in May - Nasdaq
Castle Biosciences Celebrates Skin Cancer Awareness Month - GlobeNewswire
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowe - GuruFocus
Castle Biosciences (CSTL) Rating Maintained as Price Target Lowered | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Re - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Castle Biosciences (CSTL) Target Price Reduced Despite Strong Revenue Report | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Receives Price Target Adjustment by Ca - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | C - GuruFocus
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Castle Biosciences (CSTL) Receives Price Target Adjustment by Canaccord Genuity | CSTL Stock News - GuruFocus
Canaccord Adjusts Price Target for Castle Biosciences (CSTL) | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse - FinSMEs
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... - Yahoo Finance
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: - GuruFocus
Castle Biosciences Reports Strong Q1 2025 Growth - TipRanks
Castle Biosciences to Acquire GI Health Company Previse - HIT Consultant
castle biosciences inc. Positive Earnings Pre-Announcements - RTTNews
Earnings call transcript: Castle Biosciences Q1 2025 revenue growth surpasses expectations - Investing.com Nigeria
Castle Biosciences (CSTL) to Acquire Gastrointestinal Firm Previ - GuruFocus
Castle Biosciences (CSTL) Adjusts 2025 Revenue Outlook | CSTL Stock News - GuruFocus
Castle Biosciences (CSTL) Exceeds Revenue Expectations in Q1 | CSTL Stock News - GuruFocus
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Castle Biosciences to Acquire Previse for GI Test Expansion By Investing.com - Investing.com Canada
Castle Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Castle Biosciences Reports 21% Revenue Increase in Q1 2025 - TipRanks
Castle Biosciences to buy Previse (CSTL:NASDAQ) - Seeking Alpha
Castle Biosciences To Acquire Previse - marketscreener.com
Castle Biosciences Reports First Quarter 2025 Results - The Manila Times
Castle Biosciences to Acquire Previse | CSTL Stock News - GuruFocus
Castle Biosciences to Acquire Previse for GI Test Expansion - Investing.com
Castle Biosciences Reports First Quarter 2025 Results | CSTL Stock News - GuruFocus
BRIEF-Castle Biosciences Q1 Basic EPS USD -0.9 - TradingView
Castle Biosciences to Acquire Previse - Benzinga
Castle Biosciences Acquires Johns Hopkins-Backed GI Health Company Previse to Transform Cancer Detection - Stock Titan
Wells Fargo & Company MN Boosts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Barclays PLC Sells 3,288 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Invesco Ltd. Raises Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday - Defense World
New Data at DDW 2025 Further Demonstrates the TissueCypher® - GlobeNewswire
New Clinical Data Reveals How TissueCypher Test Could Transform Early Esophageal Cancer Detection - Stock Titan
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: W - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Rating of “Buy” by Brokerages - Defense World
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Ou - GuruFocus
New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - The Manila Times
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity - GlobeNewswire
DecisionDx-Melanoma Test Achieves 97.2% Accuracy in Identifying Low-Risk Melanoma Patients - Stock Titan
Legal & General Group Plc Sells 6,356 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - Defense World
Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000 - marketscreener.com
0.94%
2.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):